PMID: 7136723Sep 1, 1982Paper

Pharmacokinetics of hydroflumethiazide during repeated administration in congestive heart failure

Acta Pharmacologica Et Toxicologica
O Brørs


The renal elimination and accumulation of hydroflumethiazide (HFT) during repeated oral administration was investigated in patients with congestive heart failure (CHF). When four doses of HFT wee given with 24 hr intervals, the mean 24 hr urinary excretion of HFT was 55-65% of the dose after 75 mg and 53-57% after 150 mg. 24 hr excretion of HFT was not significantly higher after the fourth dose as compared with the first. The renal plasma clearance of HFT was significantly correlated with creatinine clearance (P less than 0.01). The biological half-life (t1/2 beta) of HFT ranged from 6.5-27.9 hrs. Mean t1/2 beta was shorter (P less than 0.05) after 75 mg (9.2 hrs) than after 150 mg doses (14.1 hrs). The disposition rate constant of HFT was not significantly correlated with creatinine clearance or with renal plasma clearance of HFT, indicating that the volume of distribution was reduced at reduced renal function.


May 21, 1979·European Journal of Clinical Pharmacology·O Brørs, S Jacobsen
May 21, 1979·European Journal of Clinical Pharmacology·O BrørsS Jacobsen
Sep 1, 1979·European Journal of Clinical Pharmacology·O Brørs, S Jacobsen
Dec 16, 1977·European Journal of Clinical Pharmacology·W RiessM Zimmerli
Nov 9, 1978·European Journal of Clinical Pharmacology·O BrørsE Arnesen
Jan 1, 1976·Clinical Pharmacokinetics·L Dettli
Jan 1, 1977·Journal of Clinical Pharmacology·G J YakatanJ T Doluisio
Jun 1, 1972·Journal of Pharmaceutical Sciences·M Gibaldi, D Perrier
Jul 1, 1981·Journal of Pharmaceutical Sciences·V P ShahB E Cabana
Mar 1, 1961·Progress in Cardiovascular Diseases·A V GOODYER


Nov 1, 1986·Biopharmaceutics & Drug Disposition·P G Welling
Jan 28, 2014·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Mani GajendiranSengottuvelan Balasubramanian

Related Concepts

Metabolic Biotransformation
Serum Proteins
Myocardial Failure
Plasma Protein Binding Capacity

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Lipidomics & Rhinovirus Infection

Lipidomics can be used to examine the lipid species involved with pathogenic conditions, such as viral associated inflammation. Discovered the latest research on Lipidomics & Rhinovirus Infection.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Torsion Dystonia

Torsion dystonia is a movement disorder characterized by loss of control of voluntary movements appearing as sustained muscle contractions and/or abnormal postures. Here is the latest research.

Generating Insulin-Secreting Cells

Reprogramming cells or using induced pluripotent stem cells to generate insulin-secreting cells has significant therapeutic implications for diabetics. Here is the latest research on generation of insulin-secreting cells.

Central Pontine Myelinolysis

Central Pontine Myelinolysis is a neurologic disorder caused most frequently by rapid correction of hyponatremia and is characterized by demyelination that affects the central portion of the base of the pons. Here is the latest research on this disease.

Epigenome Editing

Epigenome editing is the directed modification of epigenetic marks on chromatin at specified loci. This tool has many applications in research as well as in the clinic. Find the latest research on epigenome editing here.